Why Johnson and Johnson's stock is rising in spite of the drugmaker's opioid case defeat. Two major tobacco players are in merger talks. And the performance gap between bonds and equities grows bigger. Host: Nick Jasinski. Producer: Mette Lützhøft.
Why Johnson and Johnson's stock is rising in spite of the drugmaker's opioid case defeat. Two major tobacco players are in merger talks. And the performance gap between bonds and equities grows bigger. Host: Nick Jasinski. Producer: Mette Lützhøft.